APA (7th ed.) Citation

KM, T., A, K., A, R., R, W., & SM, S. (2023). Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. IScience, 26(3), 106082. https://doi.org/10.1016/j.isci.2023.106082

Chicago Style (17th ed.) Citation

KM, Tyc, Kazi A, Ranjan A, Wang R, and Sebti SM. "Novel Mutant KRAS Addiction Signature Predicts Response to the Combination of ERBB and MEK Inhibitors in Lung and Pancreatic Cancers." IScience 26, no. 3 (2023): 106082. https://doi.org/10.1016/j.isci.2023.106082.

MLA (9th ed.) Citation

KM, Tyc, et al. "Novel Mutant KRAS Addiction Signature Predicts Response to the Combination of ERBB and MEK Inhibitors in Lung and Pancreatic Cancers." IScience, vol. 26, no. 3, 2023, p. 106082, https://doi.org/10.1016/j.isci.2023.106082.